Kisspeptin: A GnRH-Stimulating Neuropeptide for Reproductive Axis Activation

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health facilitates access to kisspeptin through licensed healthcare providers and compounding pharmacy partners. Kisspeptin is not FDA-approved for any indication. It is available by prescription only through licensed providers. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

The hypothalamic-pituitary-gonadal axis has a master regulator that sits above GnRH, above LH, and above testosterone: a neuropeptide so central to reproductive function that its absence prevents puberty from starting at all. For most of medicine's history, this molecule went unrecognized. Its discovery was accidental. Researchers studying cancer metastasis found a gene whose product suppressed tumor spread, named it KISS1, and moved on. It took another two years before anyone realized the same gene was controlling the entire reproductive hormone cascade.

Kisspeptin is that molecule. Here is what the clinical research shows about how it works, what it has been studied for, and how to evaluate whether it is relevant to you.

Key Takeaways

• Regulatory Status: As of April 2026, kisspeptin is not FDA-approved for any indication. It is available through licensed compounding pharmacies by prescription, and it has been used in hospital-based research and diagnostic protocols in the United Kingdom and United States.
• Research Stage: Active clinical research; used in fertility and diagnostic protocols in academic medical centers; available through compounding
• Availability: Not available through Superpower. Access, where available, is through licensed 503A compounding pharmacies under a patient-specific prescription from a licensed provider; prescribing represents independent clinical judgment and kisspeptin has no FDA-approved indication.
• Prescribing information: View compound reference data (PubChem CID 25077588)
• How it works: Activates GnRH neurons in the hypothalamus via the KISS1R receptor, triggering the entire HPG axis cascade.
• What the research shows: Clinical trials show kisspeptin stimulates LH, FSH, and testosterone release in men and can trigger oocyte maturation in women undergoing IVF.

What Is Kisspeptin?

Kisspeptin is a family of neuropeptides encoded by the KISS1 gene, acting as the primary upstream activator of the hypothalamic-pituitary-gonadal (HPG) axis by binding to the KISS1 receptor (KISS1R, also known as GPR54) on GnRH-secreting neurons in the hypothalamus. The active fragments range from kisspeptin-54 (a 54-amino-acid C-terminally amidated peptide) to shorter fragments including kisspeptin-14, kisspeptin-13, and kisspeptin-10, all of which share the conserved C-terminal decapeptide required for KISS1R binding and activation.

The KISS1 gene was first isolated in 1996 by Lee and colleagues, published in the Journal of the National Cancer Institute, as a metastasis-suppressor gene in human melanoma cells on chromosome 6. The gene product was named metastin for its anti-metastatic properties, and it would have remained an oncology footnote had parallel receptor science not intervened. In 2001, Ohtaki and colleagues, publishing in Nature, identified the endogenous ligand of the orphan G-protein-coupled receptor GPR54 as a 54-amino-acid peptide encoded by KISS1, establishing that kisspeptin-54 and GPR54 were a ligand-receptor pair with potent effects on downstream signaling. Simultaneously, Kotani and colleagues published in the Journal of Biological Chemistry, demonstrating that kisspeptin-54, -14, -13, and -10 all bind GPR54 with low-nanomolar affinity, explaining the biological activity of the shorter fragments that appear through proteolytic processing.

The reproductive significance of this receptor system became clear in 2003 with two landmark independent discoveries. Seminara and colleagues, publishing in the New England Journal of Medicine, identified inactivating GPR54 mutations as a cause of autosomal recessive idiopathic hypogonadotropic hypogonadism in a consanguineous family (with a second unrelated proband confirming the finding), and GPR54-knockout mice showed a matching phenotype of isolated hypogonadotropic hypogonadism — small testes, delayed vaginal opening, absent follicular maturation — while retaining normal hypothalamic GnRH content and responsiveness to exogenous GnRH and gonadotropins, pinpointing the defect at the level of GnRH neuron activation rather than GnRH synthesis. In the same year, de Roux and colleagues published independently in the Proceedings of the National Academy of Sciences USA, reporting loss-of-function GPR54 mutations causing the same phenotype in a second consanguineous family. These two papers, published within months of each other, reframed kisspeptin from a cancer biology curiosity into the master regulator of puberty and reproductive endocrine function. The key insight: without functional kisspeptin-GPR54 signaling, GnRH neurons do not fire, the pituitary receives no signal, and the gonads never activate.

How Kisspeptin Works in the Body

The upstream trigger of the HPG axis

Kisspeptin occupies a position further upstream than any other currently studied reproductive neuropeptide. The signaling hierarchy proceeds as follows: kisspeptin neurons (in the arcuate nucleus and the anteroventral periventricular nucleus of the hypothalamus) fire and release kisspeptin, which activates KISS1R on GnRH neurons, causing GnRH to be released into the hypothalamic-pituitary portal circulation, which stimulates the anterior pituitary to secrete LH and FSH, which then act on the gonads. A 2009 authoritative review by Oakley, Clifton, and Steiner in Endocrine Reviews established the neuroanatomy and physiology of kisspeptin-GnRH interactions in the brain, confirming kisspeptin as the dominant gating mechanism for hypothalamic GnRH pulse generation. A 2025 comprehensive review by Koysombat and colleagues from the Dhillo and Abbara groups at Imperial College London, published in Physiological Reviews, provides the most current synthesis of kisspeptin and neurokinin B in reproductive health, consolidating two decades of mechanistic and clinical findings.

Kisspeptin-10 vs. kisspeptin-54: the fragment story

Research and clinical protocols use different fragments of the kisspeptin family, and the choice matters for pharmacological reasons. Kisspeptin-54 is the full-length circulating form, with a longer plasma half-life than the shorter fragments and robust gonadotropin-stimulating potency demonstrated in multiple human trials. Kisspeptin-10 is the minimal active fragment (comprising only the conserved C-terminal decapeptide), with a shorter half-life that makes it useful in study designs where precise pharmacokinetic control is needed. Both fragments activate KISS1R and stimulate GnRH-driven LH secretion, but kisspeptin-54 has been the workhorse of the clinical trial program led by Professor Waljit Dhillo's group at Imperial College London, where the majority of the published human evidence originates. For researchers studying pulsatile dynamics or investigating dosing schedules where rapid clearance is an advantage, kisspeptin-10 has been employed in specific protocols.

Kisspeptin in context: upstream of GnRH, further upstream than hCG

To understand kisspeptin's position, it helps to map the signaling chain explicitly. Kisspeptin acts at the hypothalamus, driving GnRH release. GnRH (or its synthetic form, gonadorelin) acts at the pituitary, driving LH and FSH release. LH acts at the gonads, driving testosterone synthesis (in men via Leydig cells) and triggering ovulation (in women). hCG acts as an LH-receptor agonist, bypassing the entire upstream chain and stimulating the gonads directly. This hierarchy means kisspeptin is the furthest upstream intervention currently available for HPG axis stimulation. Activating kisspeptin engages the entire physiological cascade from hypothalamus to gonad. Whether that physiological completeness confers clinical advantages over more targeted downstream interventions is an active area of investigation, not an established conclusion.

What Kisspeptin Research Has Examined

1. LH, FSH, and testosterone stimulation in men

The first-in-human demonstration that kisspeptin-54 raises LH, FSH, and testosterone was published in 2005 by Dhillo and colleagues in the Journal of Clinical Endocrinology and Metabolism. In this double-blind placebo-controlled crossover study in 6 healthy men, a 90-minute IV infusion of kisspeptin-54 at 4 pmol/kg/min significantly increased mean plasma LH (10.8 vs. 4.2 U/L), FSH (3.9 vs. 3.2 U/L), and testosterone (24.9 vs. 21.7 nmol/L) compared with saline (all p < 0.001), establishing the feasibility of pharmacological HPG axis stimulation via kisspeptin in humans, though the very small sample limits the precision of the effect-size estimate. A 2007 review by Dhillo, Murphy, and Bloom in Reviews in Endocrine and Metabolic Disorders synthesized these early findings, confirming that acute IV kisspeptin potently increases plasma LH in healthy men. In men with metabolic hypogonadism, a 2013 proof-of-concept study by George and colleagues in Clinical Endocrinology administered kisspeptin-10 to 5 hypotestosteronaemic men with type 2 diabetes (with 7 age-matched healthy controls) and showed that an 11-hour IV infusion at 4 mcg/kg/h raised LH from 3.9 ± 0.1 to 20.7 ± 1.1 IU/L (p = 0.03), increased LH pulse frequency from 0.6 ± 0.1 to 0.9 pulses/h (p = 0.05), and raised testosterone from 8.5 ± 1.0 to 11.4 ± 0.9 nmol/L (p = 0.002), moving the clinical question from healthy volunteers to a patient population — though the very small cohort limits the precision of the effect-size estimate and any generalization to broader T2D-hypogonadal populations.

2. Hypothalamic amenorrhea in women

Hypothalamic amenorrhea is a condition in which reduced GnRH pulse frequency suppresses the HPG axis, typically in the context of energy deficit, excessive exercise, or psychosocial stress. Because kisspeptin sits upstream of GnRH, it is a theoretically direct way to restore pulsatile GnRH drive. Jayasena and colleagues published two critical studies from the Dhillo lab addressing this. The 2009 double-blind, randomized, parallel-design study in the Journal of Clinical Endocrinology and Metabolism randomized 10 women with hypothalamic amenorrhea 1:1 to subcutaneous kisspeptin-54 6.4 nmol/kg or saline twice daily for 2 weeks and found that acute day-1 administration raised LH by 24.0 ± 3.5 IU/L and FSH by 9.1 ± 2.5 IU/L, but by day 14 the LH rise had fallen to 2.5 ± 2.2 IU/L and FSH to 0.5 ± 0.5 IU/L (both p < 0.05 for desensitization), confirming tachyphylaxis with chronic twice-daily dosing. This is an important honesty data point: kisspeptin is not a simple daily drug. The 2010 follow-on pilot in Clinical Pharmacology and Therapeutics resolved the desensitization problem by showing that twice-weekly subcutaneous kisspeptin-54 over 8 weeks significantly elevated LH, FSH, and estradiol versus saline in women with hypothalamic amenorrhea, with only partial desensitization of FSH (versus complete tolerance on twice-daily dosing by day 2) and no reported adverse effects — establishing that intermittent dosing preserves receptor sensitivity where daily dosing had failed, though the small pilot size limits extrapolation. A 2014 single-blinded controlled trial by Jayasena and colleagues in the Journal of Clinical Endocrinology and Metabolism in 5 women with hypothalamic amenorrhea used 8-hour continuous IV kisspeptin-54 infusions at escalating doses (0.01, 0.03, 0.10, 0.30, 1.00 nmol/kg/h) versus vehicle and showed via blinded deconvolution analysis that kisspeptin-54 tripled LH pulse frequency (from 1.6 ± 0.4 to 5.0 ± 0.5 pulses per 8 hours, p < 0.01) and produced a ~6-fold rise in LH pulse secretory mass (3.92 ± 2.31 vs. 23.44 ± 12.59 IU/L, p < 0.05): not just a tonic rise, but the pulsatile GnRH-driven pattern that drives normal reproductive cycles. The very small cohort limits precision of the dose-response estimate.

3. Oocyte maturation and IVF trigger

One of the most clinically developed applications for kisspeptin is as an alternative trigger for oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization. Standard IVF protocols use hCG as the trigger for final oocyte maturation, but hCG carries a meaningful OHSS risk in high-responders due to its prolonged LH-receptor agonism. Abbara and colleagues, publishing in the Journal of Clinical Endocrinology and Metabolism in 2015, conducted a phase 2 open-label dose-finding trial in 60 women at high OHSS risk randomized across kisspeptin-54 doses of 3.2, 6.4, 9.6, and 12.8 nmol/kg and showed that 95% achieved oocyte maturation, with the highest mature-oocyte yield at the 12.8 nmol/kg dose, no woman developing moderate, severe, or critical OHSS, and clinical pregnancies occurring across dose groups — establishing feasibility of kisspeptin-54 as an IVF trigger in a high-risk population. A 2017 phase-2 randomized placebo-controlled follow-up in Human Reproduction by the same group randomized 62 women at high OHSS risk 1:1 to single (n = 31) or double (n = 31) subcutaneous kisspeptin-54 at 9.6 nmol/kg, with the second dose given 10 hours after the first, and showed that the two-dose regimen produced an additional LH surge at 4 hours and raised the proportion achieving oocyte yield ≥ 60% from 45% to 71% (absolute difference +26%, p = 0.042), with no increase in moderate OHSS in either arm. A 2018 single-center direct three-arm comparison in Clinical Endocrinology by Abbara and colleagues evaluated OHSS outcomes across hCG (n = 40), GnRH agonist (n = 99), and kisspeptin (n = 122) triggers, and found the odds ratio for OHSS diagnosis versus kisspeptin was 33.6 (95% CI 12.6–89.5) for hCG and 3.6 (1.8–7.1) for GnRH agonist, with kisspeptin also showing the smallest median ovarian volume (44 vs. 138 ml for hCG and 73 ml for GnRHa) and least ascitic fluid — the strongest single citation for kisspeptin's potential safety advantage in this application, though the observational, single-center design warrants confirmation in head-to-head randomized trials.

4. Hypogonadotropic hypogonadism and delayed puberty

The diagnostic and therapeutic potential of kisspeptin in hypogonadotropic hypogonadism extends beyond the mechanism studies. A 2016 study by Lippincott and colleagues in JCEM examined kisspeptin responsiveness as a biomarker of emerging reproductive endocrine activity in adolescents, establishing a dose-response relationship between kisspeptin challenge doses and GnRH-driven LH secretion. A 2018 study by Chan, Lippincott, and colleagues in JCI Insight administered IV kisspeptin and GnRH boluses to 15 children (11 boys, 4 girls) with delayed or stalled puberty before and after 6 days of GnRH priming and found a clear bimodal LH response — 7 responders with adult-male-pattern kisspeptin responses versus 7 non-responders with no LH response (plus 1 intermediate), with 6 of 7 responders showing spontaneous LH pulses at baseline, supporting kisspeptin as a diagnostic probe for distinguishing transient delayed puberty from permanent hypogonadotropic hypogonadism. The small cross-sectional cohort prevented definitive prognostic conclusions, and longer follow-up is needed to confirm that kisspeptin responsiveness predicts pubertal progression. A 2020 clinical study by Abbara, Eng, Phylactou, and colleagues in the Journal of Clinical Investigation evaluated the kisspeptin receptor agonist MVT-602 against native kisspeptin-54 across 9 healthy women in follicular phase, 6 women with PCOS, and 6 women with hypothalamic amenorrhea, using subcutaneous MVT-602 at 0.01 or 0.03 nmol/kg versus kisspeptin-54 at 9.6 nmol/kg, and showed that MVT-602 produced an LH peak at 21.4 vs. 4.7 hours for KP54 (p = 0.0002) with comparable amplitude but greater area under the curve, and in vitro produced longer-duration GnRH neuron firing (115 vs. 55 minutes, p = 0.0012), supporting the therapeutic development of kisspeptin receptor agonists for female reproductive disorders. The small subgroup Ns limit precision of the PCOS- and HA-specific response estimates.

5. Sexual and emotional brain processing

Kisspeptin's effects are not limited to the HPG axis. The same receptor system appears to modulate brain responses to sexual and emotional stimuli through pathways that are at least partially independent of gonadotropin release. A 2017 double-blind, placebo-controlled fMRI study by Comninos and colleagues, published in the Journal of Clinical Investigation, demonstrated that kisspeptin-54 administration modulates brain activity in regions governing sexual and emotional processing in healthy men. A 2018 resting-state fMRI follow-up in JCI Insight by Comninos and colleagues showed kisspeptin enhances functional connectivity in brain networks supporting sexual and emotional function. A 2020 study by Yang and colleagues in JCI Insight extended these findings, showing kisspeptin enhances brain responses to olfactory and visual attraction cues in men. The clinical translation of these neuroimaging findings into outcomes-level evidence has been tested in two randomized controlled trials: a 2022 randomized, double-masked, placebo-controlled crossover RCT by Thurston and colleagues in JAMA Network Open in 32 premenopausal women (mean age 29.2 years) with HSDD used IV kisspeptin-54 at 1 nmol/kg/h for 75 minutes versus placebo and found kisspeptin modulated sexual-processing regions including deactivation of the left inferior frontal gyrus (Z = 3.76, p = 0.01) and activation of the right postcentral/supramarginal gyrus (Z = 3.73, p < 0.001), with hippocampal activity correlating with baseline sexual distress (r = 0.469, p = 0.007) and no reported adverse effects, while a parallel 2023 double-blind, 2-way crossover RCT by Mills and colleagues in JAMA Network Open in 32 heterosexual men (mean age 37.9 years) with HSDD used IV kisspeptin-54 at 1 nmol/kg/h for 75 minutes versus placebo and demonstrated significant modulation of sexual-processing brain regions (Cohen d = 0.81, p = 0.003), increased penile tumescence by up to 56% more than placebo (p = 0.02), and improved self-reported happiness about sex (mean difference 0.63 points, p = 0.02). These are the highest-quality citations for the sexual function research line, and they represent imaging and behavioral data, not definitive outcomes trials.

Kisspeptin vs. Gonadorelin vs. hCG: How They Differ

These three compounds all ultimately aim to activate gonadal hormone production, but they differ in where they enter the signaling cascade. This comparison is for scientific context only. These compounds have fundamentally different evidence bases, regulatory statuses, and clinical applications.

Kisspeptin sits furthest upstream, activating KISS1R on GnRH neurons in the hypothalamus and triggering the entire downstream cascade from GnRH to LH and FSH to gonadal hormone production. Its gonadotropin-stimulating effect depends on intact GnRH neurons, a responsive pituitary, and functional gonads: three links in the chain rather than one. Gonadorelin (synthetic GnRH) enters the cascade one step lower, acting directly on pituitary gonadotroph cells to stimulate LH and FSH release, bypassing the hypothalamic step but still requiring a responsive pituitary and functional gonads. hCG acts at the lowest level, binding directly to the LH/hCG receptor on Leydig cells (in men) or granulosa-lutein cells (in women) to drive gonadal steroidogenesis without requiring either a functional hypothalamus or pituitary.

The practical implication is that kisspeptin requires the most steps to produce a gonadal response, which may confer physiological advantages (activating the full pulsatile feedback-regulated cascade) or disadvantages, depending on where in the axis a deficiency lies. A man with primary hypogonadism (testicular failure) will not respond to kisspeptin because the final effector is non-functional. A man with secondary hypogonadism and an intact pituitary is theoretically a better candidate. The kisspeptin research base is strongest for hospital-based diagnostic and fertility research applications; the evidence for its use as a compounded therapeutic in conditions like functional hypogonadism is earlier stage than the evidence base for gonadorelin or hCG in analogous indications.

Biomarkers to Monitor With Kisspeptin

Kisspeptin's clinical effect is mediated entirely through HPG axis stimulation, and the markers below directly track whether that cascade is being engaged and what the gonadal response looks like. Establishing these values before any intervention provides the reference point needed to evaluate a response.

• Luteinizing hormone (LH): The immediate pituitary output in response to GnRH stimulation, which kisspeptin drives. Baseline LH distinguishes between primary and secondary hypogonadism and confirms whether the hypothalamic-pituitary arm of the axis is intact and responsive. A measurable LH rise after kisspeptin administration is the direct pharmacological proof that KISS1R signaling has reached the pituitary. When to test: baseline and at follow-up intervals during therapy.
• Follicle-stimulating hormone (FSH): Released alongside LH in response to GnRH pulses, FSH drives spermatogenesis in men and follicular development in women. Baseline FSH is essential context for interpreting gonadal reserve and predicting HPG axis responsiveness. In women being evaluated for hypothalamic amenorrhea or as IVF candidates, FSH also reflects ovarian reserve status. When to test: baseline and follow-up.
• Total testosterone: The primary downstream outcome marker in men undergoing HPG axis stimulation. Kisspeptin's gonadotropin-stimulating effect should translate into increased LH-driven Leydig cell testosterone synthesis in men with intact testicular function. Establishing a baseline before any intervention is essential for evaluating response. When to test: baseline and follow-up.
• Free testosterone: The biologically active fraction not bound to SHBG or albumin. In men with elevated SHBG (common in older men and in metabolic states associated with hypogonadism), total testosterone may overstate available androgen, making free testosterone a necessary complement to total testosterone interpretation. When to test: baseline alongside total testosterone.
• Estradiol: Testosterone aromatizes to estradiol in peripheral tissue. Estradiol exerts negative feedback on kisspeptin neuron activity and on GnRH secretion, a regulatory loop that shapes the natural pulsatile pattern of the reproductive axis. Monitoring estradiol during HPG axis stimulation provides information about aromatization rates and helps evaluate whether downstream feedback is responding appropriately. In women, estradiol is a primary marker of follicular activity and ovarian response. When to test: baseline and follow-up.
• Sex hormone-binding globulin (SHBG): Binds testosterone in circulation and reduces the free fraction. SHBG levels are substantially influenced by metabolic status, liver function, thyroid status, and age. A baseline SHBG measurement is essential for interpreting testosterone values in context, and changes in SHBG during any intervention affect how testosterone results should be read. When to test: baseline.
• Prolactin: Elevated prolactin independently suppresses GnRH pulse frequency and LH secretion, making it a reversible cause of secondary hypogonadism that must be ruled out before attributing low gonadotropins to another cause. A baseline prolactin value confirms that hyperprolactinemia is not the underlying driver before any HPG axis intervention is considered. When to test: baseline.

What Kisspeptin Is Typically Used For in Research and Clinical Contexts

Kisspeptin has been used in three principal research and clinical contexts: hospital-based diagnostic evaluation of the HPG axis (including distinguishing transient delayed puberty from permanent hypogonadotropic hypogonadism), fertility medicine (particularly as an IVF trigger in women at high OHSS risk, as developed through the Dhillo and Abbara research program at Imperial College London), and investigational human studies of hypothalamic amenorrhea and sexual function. In each case, access has been through academic medical center protocols or, more recently, through licensed compounding pharmacies with a prescribing provider. Kisspeptin requires intact GnRH neurons, a responsive anterior pituitary, and functional gonads to produce a gonadal hormone response. Providers evaluating candidacy will confirm secondary rather than primary gonadal dysfunction before kisspeptin is considered relevant to the clinical picture.

Who Should Not Use Kisspeptin

A licensed provider will evaluate individual risk factors before prescribing. The following represent conditions requiring additional clinical scrutiny or representing contraindications:

• Primary hypogonadism (testicular or ovarian failure, including Klinefelter syndrome): kisspeptin drives gonadotropin release but cannot produce a gonadal hormone response if the gonads are non-functional, as the downstream target is absent
• Active or history of hormone-sensitive malignancy, including prostate cancer or estrogen-receptor-positive breast cancer: HPG axis stimulation elevates gonadal hormones and may affect disease progression
• Active use of GnRH antagonists or GnRH agonists at continuous therapeutic doses: continuous GnRH receptor occupancy would be expected to interact with any upstream kisspeptin-driven GnRH signal in pharmacologically complex ways
• Pregnancy: no safety data exists for kisspeptin administration during pregnancy; the compound is a master regulator of reproductive endocrinology, making exogenous administration during gestation inappropriate outside specific monitored protocols
• Known hypersensitivity to kisspeptin or related peptide compounds
• Individuals not willing to undergo baseline and follow-up hormone monitoring: responsible use requires objective tracking of HPG axis response

A licensed provider will conduct a full clinical evaluation, including baseline bloodwork, before determining eligibility. This list is not exhaustive.

Side Effects and Safety Considerations

The published human clinical data on kisspeptin (largely from the Dhillo lab at Imperial College London) characterizes its safety profile in the contexts studied: primarily short-duration IV infusion, subcutaneous injection research protocols, and single-dose IVF trigger applications.

Common (reported in clinical studies):

• Transient LH and FSH surges (the intended pharmacological effect, which can produce downstream hormonal fluctuations as a consequence)
• Mild injection-site discomfort with subcutaneous administration
• Tachyphylaxis (receptor desensitization) with chronic daily dosing, documented by Jayasena and colleagues in the 2009 hypothalamic amenorrhea study; intermittent dosing schedules appear to preserve receptor responsiveness

Less common or incompletely characterized:

• Ovarian hyperstimulation syndrome: substantially lower risk than with hCG triggers in IVF based on Abbara 2018 comparison data, but not completely absent in all study contexts; providers monitoring IVF protocols assess OHSS risk at baseline
• Hot flushes and transient estradiol fluctuations in women, consistent with acute gonadotropin surges
• Long-term safety profile of compounded subcutaneous kisspeptin as a chronic therapeutic is not fully characterized as of April 2026; most published human data involves acute or short-course research protocols rather than extended chronic use

Scott and colleagues published a phase 1 double-blind, randomized, placebo-controlled study of TAK-683 (a metastin analog) in the British Journal of Clinical Pharmacology in 2013 across two cohorts of healthy men — a single-dose study (n = 60; 42 active, 18 placebo) at subcutaneous doses of 0.01-2.0 mg and a 14-day continuous-infusion study (n = 30; 25 active, 5 placebo) — documenting safety comparable to placebo across all dose levels with no serious adverse events, while continuous dosing produced paradoxical downregulation at high doses: 2.0 mg/day suppressed testosterone below castration level (<50 ng/dL) in 4 of 5 subjects by day 7, with LH and FSH falling by up to 70% and 43% respectively. TAK-683 is a synthetic analog, not kisspeptin itself, and the continuous-infusion desensitization signal reinforces the broader class finding that receptor-agonist duration matters — the same tachyphylaxis principle Jayasena and colleagues characterized for kisspeptin-54 itself — but it provides directional context about the acute-safety signals relevant to this receptor class.

Is Kisspeptin Legal?

As of April 2026, kisspeptin is not FDA-approved for any indication. There is no NDA or ANDA for any kisspeptin product in the United States. Its clinical use to date has been primarily within academic medical center research protocols in the United Kingdom and United States, and in licensed hospital-based diagnostic and fertility procedures. No FDA-approved prescribing label exists, and no DailyMed entry is available for kisspeptin.

Kisspeptin is available through licensed 503A compounding pharmacies with a valid prescription from a licensed provider. It is not available over the counter. Compound reference data is available at PubChem (CID 25077588 for kisspeptin-10). Any prescribing of compounded kisspeptin represents the independent clinical judgment of the provider, applied in a context without an FDA-approved indication. Products sold online without a prescription and without pharmacy oversight are unregulated, lack quality controls, and may not contain what they represent. As of April 2026, kisspeptin does not appear on the WADA Prohibited List as a specifically named substance, though athletes subject to anti-doping rules should consult their governing body, as WADA's S2 category (peptide hormones, growth factors, related substances, and mimetics) is broadly defined and may encompass compounds that stimulate endogenous hormone production.

Understanding Your Baseline Before Starting Kisspeptin

Kisspeptin's mechanism is entirely mediated through HPG axis stimulation. Without a baseline measurement of LH, FSH, total testosterone, and estradiol, there is no reference point against which to evaluate whether the compound is having its intended effect, whether dosing requires adjustment, or whether the HPG axis is responding appropriately at each step of the cascade. The 2013 George study in men with type 2 diabetes and hypogonadism characterized both the kisspeptin-10 dose response and the LH and testosterone trajectories together, because neither measurement is interpretable without the other. A provider evaluating candidacy for kisspeptin therapy will also need to confirm that the HPG axis deficit is central (secondary) rather than gonadal (primary), a distinction that requires LH and FSH values in the context of low testosterone or reproductive dysfunction. Prolactin, SHBG, and estradiol complete the picture of where the axis stands before any intervention.

The principle that understanding your biology should precede any clinical decision is central to Superpower's approach to preventive health. Objective biomarker data (the kind that shows exactly where the markers relevant to libido and fertility stand before any intervention) is the foundation that makes every subsequent data point interpretable.

IMPORTANT SAFETY INFORMATION

Kisspeptin is not FDA-approved for any indication as of April 2026. No NDA or ANDA for kisspeptin has been submitted to or approved by the FDA. Superpower Health does not prescribe, sell, compound, or facilitate access to kisspeptin; this page is provided for educational and informational purposes only.

Compounded kisspeptin is prepared by a licensed 503A compounding pharmacy and is not an FDA-approved drug product. It has not been evaluated by the FDA for safety, efficacy, or manufacturing quality in the manner required for drug approval. Purity, potency, and sterility of compounded preparations depend on individual pharmacy standards and are not subject to FDA manufacturing oversight.

Do not use kisspeptin if you have: primary hypogonadism or gonadal failure; active or history of hormone-sensitive malignancy (including prostate cancer, estrogen-receptor-positive breast cancer); known hypersensitivity to kisspeptin or related peptide compounds; or are currently receiving continuous GnRH agonist or antagonist therapy for cancer or other indications. Kisspeptin is not for use during pregnancy. Safety in pregnancy has not been established.

Warnings: tachyphylaxis (receptor desensitization) with chronic daily dosing; hormonal fluctuations from acute gonadotropin surges; potential for OHSS in women undergoing ovarian stimulation protocols (risk is substantially lower than with hCG triggers based on published comparison data but is not absent); transient estradiol fluctuations. Long-term safety profile of compounded kisspeptin as a chronic therapeutic has not been characterized in controlled trials as of April 2026.

Common side effects in research protocols: transient LH and FSH surges; mild injection-site discomfort with subcutaneous administration; hot flushes in women from acute gonadotropin-driven estradiol changes.

Not available in all states. Availability of compounded kisspeptin is subject to state pharmacy board regulations and individual prescriber judgment. All prescribing of compounded kisspeptin represents the independent clinical judgment of the prescribing physician and is not an FDA-approved indication.

Additional Questions

What is the connection between kisspeptin and sexual desire?

Clinical fMRI research from the Dhillo lab, including RCTs published in JAMA Network Open in 2022 and 2023, shows kisspeptin modulates brain activity in regions governing sexual and emotional processing in both men and women with HSDD. These are brain-imaging and behavioral data, not definitive outcomes trials establishing kisspeptin as an approved sexual function therapy. The mechanism appears to involve KISS1R signaling in limbic and cortical regions independent of or in addition to its HPG axis effects.

How does kisspeptin compare to gonadorelin?

Kisspeptin acts one step further upstream than gonadorelin. Kisspeptin activates hypothalamic GnRH neurons via KISS1R; gonadorelin (synthetic GnRH) is what those neurons release to act on the pituitary. Both require an intact pituitary and functional gonads to produce a downstream hormone response. Gonadorelin has more established clinical evidence in specific indications (congenital hypogonadotropic hypogonadism managed with pulsatile pump therapy). Kisspeptin's evidence base is strongest in fertility research, HPG axis diagnostics, and the emerging sexual function research line.